Anal Botulinum Toxin in Children with Hirschsprung Disease and Functional Constipation: A Prospective Cohort study.

Journal: European Journal Of Pediatric Surgery : Official Journal Of Austrian Association Of Pediatric Surgery ... [Et Al] = Zeitschrift Fur Kinderchirurgie

Background:  Anal sphincter botulinum toxin injections (BTIs) are used in the treatment of children with severe defecation disorders, including Hirschsprung disease (HD) and functional constipation (FC). Our objective was to evaluate the outcomes of BTI in these children.

Methods:  We performed a prospective cohort study of children undergoing BTI from July 2018 to December 2018. We recorded perceived effect of the BTI, including effectiveness ranging from 0 (not at all effective) to 4 (extremely effective). In addition, we recorded symptoms and the Cleveland Clinic Constipation Score (CCCS). Data were collected at baseline and at 2 weeks, 2 months, and 4 months post-injection.

Results:  Forty-two children (HD = 25, FC = 17) were included in the study (median age 4.3 years, IQR 2.4-7.2, 52% male). Twenty-two (88%) children with HD and eight (47%) children with FC had previously undergone a BTI. BTIs were perceived effective in 16 (76%) and 12 (71%) children with HD and eight (47%) and seven (47%) children with FC at 2 weeks and 2 months follow-up, respectively. Effectiveness was not rated differently between groups except at the 2-month follow-up, when patients with HD rated the BTI more effective compared to those with FC (median 2 [HD] vs. median 1 [FC], p = 0.022). Over the course of the study, 17/39 (44%) children reported self-limiting adverse effects such as fecal incontinence and pain at the injection site.

Conclusions:  Anal sphincter BTIs can be effective in the treatment of constipation in both HD and FC patients.

Desiree Baaleman, Alexandra Hallagan, Devin Halleran, Danielle Orsagh Yentis, Marc Levitt, Richard Wood, Marc Benninga, Neetu Bali, Karla Vaz, Desale Yacob, Carlo Di Lorenzo, Peter Lu

Similar Publications